Illumina, Inc.(NASDAQ : ILMN)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|REGN||Regeneron Pharmaceuticals, Inc.||2.71%||461.57||2.7%||$556.12m|
|GILD||Gilead Sciences, Inc.||2.20%||64.62||1.0%||$516.91m|
|VRTX||Vertex Pharmaceuticals, Inc.||2.02%||211.98||1.9%||$458.30m|
|ALXN||Alexion Pharmaceuticals, Inc.||1.11%||150.10||2.0%||$339.49m|
|CRSP||CRISPR Therapeutics AG||-0.73%||114.65||0.6%||$304.78m|
|BNGO||BioNano Genomics, Inc.||3.62%||7.15||0.0%||$275.81m|
|EXAS||EXACT Sciences Corp.||0.51%||121.64||18.4%||$251.13m|
|PACB||Pacific Biosciences of California, Inc.||1.70%||29.27||7.2%||$176.23m|
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services; proactive instrument monitoring; and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.